Raleigh, NC – According to filings with the U.S. Securities and Exchange Commission, Inanovate is raising $1,807,117.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, David Ure played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Inanovate
Inanovate was founded in Massachusetts by two Babson MBA graduates, after winning first prize at the Babson Business Plan competition. The company has since grown operations in Massachusetts, North Carolina and the UK, forming close alliances with leading commercial and academic institutions. Inanovate has combined expertise from nano-scale physics, bio-engineering, bio-chemistry and biotechnology to create a unique mutliplexed protein screening technology called Longitudinal Assay Screening (LAS), designed to help advance the development and implementation of next generation therapeutics and clinical diagnostics. Inanovate has recently completed testing and demonstration of the worlds first protein detection and measurement platform to integrate LAS – The Bio-ID 400. Inanovate is now seeking to build on its technical and commercial foundations through partnerships with companies seeking to develop, validate and launch multiplexed protein assays for selected research or clinical applications.

To learn more about Inanovate, visit http://inanovate.com/

Contact:
David Ure, Chief Executive Officer
919-410-8973
dure@inanovate.com
https://www.linkedin.com/in/daveure/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved